Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2024-04-09 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Phase 2 Trial Reaches 50% Recruitment 3 pages 133.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 10 April 2024 from Syntara Limited announcing the achievement of a 50% recruitment milestone in a Phase 2 clinical trial for their lead drug candidate SNT-5505. It discusses trial progress, expected interim results, and future plans for FDA engagement and pivotal study design. The content is focused on clinical trial updates and company progress rather than financial results, regulatory filings, or shareholder information. There is no indication that this is a financial report, earnings release, regulatory filing, or any other formal report type. It is a corporate announcement providing an update on clinical development milestones and future expectations. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which serves as a general category for announcements that do not fit other specific filing types.
2024-04-09 English
Investor presentation - NWR Virtual Healthcare Conference 19 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from a virtual healthcare conference dated March 2024, featuring the CEO of Syntara. It includes extensive information about the company's clinical trials, drug pipeline, financial data, shareholder information, board leadership, scientific research, and market opportunities. The content is structured as a presentation with forward-looking statements, clinical trial updates, financial highlights, and strategic positioning. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting or dividend announcement. The document is clearly designed to inform investors and stakeholders about the company's strategy, clinical progress, and financial position in a presentation format. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-03-18 English
SNT to present at NWR Virtual Healthcare Conference 2 pages 118.7KB
Investor Presentation Classification · 85% confidence The document is a media release announcing that Syntara Ltd will present at the NWR Virtual Healthcare Conference on 20 March 2024. It includes details about the presentation, how to register, and background information about the company and its drug development pipeline. There are no financial statements, earnings data, or detailed investor presentations included. The document is an announcement of an upcoming event rather than a report or transcript. It does not fit into categories like Earnings Release, Annual Report, or Call Transcript. The best fitting category is Investor Presentation (IP) because it relates to a presentation aimed at investors and interested parties, even though the actual presentation content is not included here, the announcement is about the presentation event itself. Given the document length and content, confidence is high but not absolute since it is an announcement of a presentation rather than the presentation itself.
2024-03-13 English
Investor Presentation 21 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is a detailed investor briefing dated March 6, 2024, containing extensive information about the company's clinical trials, financial position, strategic focus, management team, and scientific background. It includes forward-looking statements, clinical trial interim results, financial data, and strategic updates. The content is comprehensive and includes substantive financial and operational data, not just an announcement or summary. It is not a transcript of a call, nor a regulatory filing or certification. It is not a full annual report or audit report but rather a detailed presentation aimed at investors covering financials, strategy, and market position. Therefore, the document best fits the category of an Investor Presentation (IP).
2024-03-05 English
Change in substantial holding 6 pages 883.2KB
Regulatory Filings Classification · 90% confidence The provided document text is almost entirely composed of placeholders indicating omitted pictures and does not contain any readable text, titles, regulatory references, fiscal period dates, or any substantive content. There is no indication of the document being a report itself or an announcement of a report. The length is 15,000 characters, which is substantial, but the content is not visible or interpretable. Without any textual clues or financial data, it is impossible to classify this document into any specific filing category based on the given definitions. According to the rules, if a document does not neatly fit into any specific category due to lack of information, it should be classified as Regulatory Filings (RNS), which is the fallback category.
2024-03-03 English
Application for quotation of securities - SNT 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used for the application for quotation of securities. It details the issuance and quotation of new securities resulting from the exercise of options or conversion of convertible securities. The document includes specifics such as the number of securities, issue date, and whether the securities are part of an employee incentive scheme. This type of announcement is related to changes in the company's capital structure, specifically the issuance and quotation of new shares. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital change. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-02-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.